Anti-CD19 CAR-T cell therapy (Juno Therapeutics)

抗CD19 CAR-T细胞疗法

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (Juno Therapeutics)

Drug Alias NameCD19-directed 4-1BBL armored CAREGFRt/19-28z/4-1BBL CAR T cellsArmored CAR modified T Cells

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJuno Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesJuno Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A